Articles from IGI, Inc.

NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Ichnos Glenmark Innovation, Inc. (IGI), a global clinical-stage biotechnology company developing Multispecific™ therapeutics in oncology, today announced that updated clinical data from the Phase 1 study of ISB 2001 (ABBV-2001) in relapsed/refractory multiple myeloma (RRMM) will be presented as an oral presentation at the 68th American Society of Hematology (ASH) Annual Meeting.

Physician-Scientist with Proven Track Record of Global Drug Development and Regulatory Approvals to Lead Clinical Development of IGI’s Multispecific™ Oncology Pipeline

Next-generation multispecific antibody, ISB 2301, targets 3 tumor-associated antigens (TAAs) and activates both T cells and natural killer (NK) cells

NEW YORK and NORTH CHICAGO, Ill., July 10, 2025 (GLOBE NEWSWIRE) -- IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation, Inc. (IGI), and AbbVie (NYSE: ABBV) today announced an exclusive licensing agreement for IGI’s lead investigational asset, ISB 2001, developed using IGI’s proprietary BEAT® protein platform, for oncology and autoimmune diseases.

TRIgnite-1 study shows an overall response rate (ORR) of 74% across nine dose levels, in heavily pretreated patients with a median of six prior lines of therapy

Results from the dose-escalation portion of the Phase 1 clinical study of ISB 2001 in patients with heavily pretreated multiple myeloma to be presented at the 2025 ASCO Annual Meeting